Crispr Therapeutics AG (CRSP) stock is up 125.79% over the last 12 months, and the average rating from Wall Street analysts is a Buy. InvestorsObserver’s proprietary ranking system, gives CRSP stock a score of 29 out of a possible 100.

That rank is primarily influenced by a fundamental score of 21. In addition to the average rating from Wall Street analysts, CRSP stock has a mean target price of 163.8. This means analysts expect the stock to fall 1.28% over the next 12 months. CRSP's rank also includes a short-term technical score of 30. The long-term technical score for CRSP is 35.

Overall Score - 29
CRSP has an Overall Score of 29. Find out what this means to you and get the rest of the rankings on CRSP!

What's Happening with CRSP Stock Today

Crispr Therapeutics AG (CRSP) stock is up 10.26% while the S&P 500 is up 0.05% as of 1:31 PM on Wednesday, Jun 30. CRSP is up $15.43 from the previous closing price of $150.49 on volume of 4,172,317 shares. Over the past year the S&P 500 is higher by 38.51% while CRSP is up 125.79%. CRSP lost -$5.62 per share in the over the last 12 months.

Click Here to get the full Stock Score Report on Crispr Therapeutics AG (CRSP) Stock.



Source link